Recent

% | $
Quotes you view appear here for quick access.

Albany Molecular Research Inc. Message Board

agoodlaughtoday 85 posts  |  Last Activity: Jan 24, 2013 12:43 PM Member since: Jan 4, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Why the huge drop early today?

    by tough1er Jan 22, 2013 10:19 AM
    agoodlaughtoday agoodlaughtoday Jan 24, 2013 12:43 PM Flag

    you seem in the know did the Burlington Ma plant were get the green light from the FDA to go back into production?

  • Reply to

    Quarterly figs

    by bty70708320 May 9, 2012 9:48 AM
    agoodlaughtoday agoodlaughtoday Nov 7, 2012 1:01 PM Flag

    Agreed. Todays q figures not too bad either. Seems a goodlaughtoday might have been missing something after all....;)

    Well if you look at year in total, and that Q3 2011 was lower than Q3 2010 i.e. only 10% increase over two years and half that growth is royalties………
    Total revenue for the nine-month period ended September 30, 2012 was $159.5 million, a decrease of $1.6 million or 1% compared to $161.1 million for the same period in 2011.

    And how is the purchase of Hyaluron in Mass doing????? Still no FDA approval after two years
    Contract revenue for Development/Small-Scale Manufacturing in the nine-month period ended September 30, 2012 was $25.2 million, a decrease of 12% from $28.7 million in 2011.

    I’ll stand by my statement

  • Reply to

    another one gone

    by agoodlaughtoday Sep 14, 2012 12:44 PM
    agoodlaughtoday agoodlaughtoday Oct 23, 2012 12:03 PM Flag

    and one gets a new title and more money

  • agoodlaughtoday by agoodlaughtoday Sep 14, 2012 12:44 PM Flag

    I see Frost has taken the hit for bad leadership, did all the other people asked to leave get 16 months pay?

  • Reply to

    Quarterly figs

    by bty70708320 May 9, 2012 9:48 AM
    agoodlaughtoday agoodlaughtoday May 9, 2012 12:24 PM Flag

    you are missing something, sales are flat not a good thing shows the company is not getting new customers

    Total contract revenue for the first quarter of 2012 was $42.7 million, consistent with total contract revenue of $42.9 million reported in the first quarter of 2011.
    Total contract revenue encompasses revenue from AMRI's Discovery Services, Development and Small Scale Manufacturing, and Large Scale Manufacturing business components.
    Discovery Services contract revenue for the first quarter was $9.7 million, a decrease of 8% from $10.6 million in 2011
    Development/Small Scale Manufacturing contract revenue for the first quarter was $9.8 million, a decrease of 7% from $10.5 million in 2011
    Large Scale Manufacturing contract revenue for the first quarter was $23.2 million, an increase of 6% from $21.8 million in 2011

  • Reply to

    Close the Doors

    by tstockpicker Mar 23, 2012 9:17 AM
    agoodlaughtoday agoodlaughtoday Mar 24, 2012 10:42 AM Flag

    That's too simplistic of an analysis. What you have is a management team, which purchased at what they perceived as a steal underperforming assets, which in reality they overpaid for. Coupled with the arrogance that it wasn't their fault that they didn't understand the pharmaceutical market was reducing R&D expenditures which in my opinion, the management teams of the companies that sold AMRI the underperforming sites understood and cleverly conveyed the opposite to AMRI's senior management team.
    If it wasn't for the Rensselaer cash cow the underperformance of the acquired sites, i.e., Massachusetts, UK and Hungary would be glaringly apparent. If this failure of adequately performing due diligence had been conducted by a junior member of AMRI management team the pro-AMRI senior management employees who post on this board would have already lamented the fact.
    When you watch a management team in action sometimes, what they don't discuss in press releases is as important as what they do. An example there has been no press releases about new revenue opportunities emerging from the acquired UK and Massachusetts site's

  • Reply to

    What happened to the cash?

    by mkozak09 Dec 7, 2011 9:32 PM
    agoodlaughtoday agoodlaughtoday Dec 8, 2011 3:58 PM Flag

    26 million went to Burlington site

  • TUCSON, Ariz.--(BUSINESS WIRE)-- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the SynCardia temporary Total Artificial Heart, announced today that the world's first three Total Artificial Heart patients have been discharged from SynCardia Certified Centers using the new Freedom(TM) portable driver. Weighing 13.5 lbs, the Freedom driver is the world's first wearable portable driver designed to power SynCardia's Total Artificial Heart both inside and outside the hospital.

    1st European Patient - Nantes, France

    University Hospital of Nantes switched Europe's first Total Artificial Heart patient to a Freedom driver on May 21, and discharged 36-year-old Eric Quantin on May 28. "He really appreciated the increased mobility that the Freedom driver gave him and was very happy to be at home," said Prof. Daniel Duveau, Medical Director of the Thorax Institute at University Hospital of Nantes. "The patient received a matching donor heart three days later and is in good condition."
    World's 1st Female Patient - Moscow, Russia

    The Bakoulev Scientific Center for Cardiovascular Surgery placed the first female Total Artificial Heart patient on a Freedom driver on May 21 and discharged her home on June 4. Tatyana, 60, was the world's 850th recipient of the Total Artificial Heart. Using the Freedom portable driver, Tatyana was able to visit with her first grandson, who was born just days after she received the Total Artificial Heart.
    1st U.S. Participant in IDE Clinical Study - Phoenix, Arizona

    On May 3, a Phoenix-area SynCardia Certified Center discharged the first U.S. Total Artificial Heart patient as part of the FDA Investigational Device Exemption (IDE) clinical study of the Freedom driver. Charles Okeke, a 43-year-old father of three, surpassed 50 days of support with the Freedom driver at home on June 22. The IDE clinical study is designed to demonstrate that the Freedom driver is a suitable pneumatic driver for stable Total Artificial Heart patients and can be used safely at home.

  • agoodlaughtoday agoodlaughtoday Jun 8, 2010 9:52 PM Flag

    We recorded write-downs of inventory in the amount of $3.5 million, $1.4 million, and $1.0 million for fiscal 2010, 2009, and 2008, respectively.

  • Reply to

    Inventory Issues

    by seyodog1 Oct 13, 2008 12:50 PM
    agoodlaughtoday agoodlaughtoday Jan 3, 2010 10:26 PM Flag

    let's bring old post back

  • agoodlaughtoday by agoodlaughtoday Jan 3, 2010 8:49 PM Flag

    well this stock lost 1/2 it's value last year.
    my guess for 2010 is be that sales will be so/so and the stock will end 2010 in the 4-6 range

    see you in a year

  • Reply to

    The most unheard of thing I've ever heard of

    by seyodog1 Nov 5, 2009 10:19 AM
    agoodlaughtoday agoodlaughtoday Nov 10, 2009 11:19 AM Flag

    the old Abiomed product lines have seen a sales drop of over half. This is becoming a one product company

    2009 2008
    Other 6,549 9,270 14,110 19,748

  • Reply to

    Impella taking off

    by rxpert10 Sep 15, 2009 1:50 PM
    agoodlaughtoday agoodlaughtoday Sep 22, 2009 7:25 PM Flag

    No it's management, with believes it's own sales forecast projections thereby believing it does not have sufficient manufacturing capacity. Then keyword, then squander $2 million to build capacity for nonexistent sales this is something they've been doing for the last three years it’s not $2 million it is closer to $5 million if you factor in the money they scrapped last year due to lower sales volumes.
    So for you insiders who keep trying to negate poor planning and judgment. Instead of facing the facts, your pompous arrogance continues to cost shareholders money. Now that's sarcastic

  • Reply to

    Impella taking off

    by rxpert10 Sep 15, 2009 1:50 PM
    agoodlaughtoday agoodlaughtoday Sep 17, 2009 11:33 AM Flag

    then why
    We have deferred the start up activities at our Athlone, Ireland manufacturing facility and plan to monitor the capacity enhancements in Aachen, Germany prior to finalizing the location of a second production line. As of June 30, 2009, we have invested $2.0 million of capital expenditures at the Athlone facility.

  • We have deferred the start up activities at our Athlone, Ireland manufacturing facility and plan to monitor the capacity enhancements in Aachen, Germany prior to finalizing the location of a second production line. As of June 30, 2009, we have invested $2.0 million of capital expenditures at the Athlone facility.

  • Reply to

    OK- how about some news from the company???

    by poolornament Jul 22, 2009 9:55 AM
    agoodlaughtoday agoodlaughtoday Jul 22, 2009 1:02 PM Flag

    no news is always bad news

  • Reply to

    Inventory Issues

    by seyodog1 Oct 13, 2008 12:50 PM
    agoodlaughtoday agoodlaughtoday Jun 12, 2009 1:10 PM Flag

    PERIOD ENDING 31-Mar-09 31-Dec-08 30-Sep-08 30-Jun-08
    Total Revenue 19,583 17,271 19,999 16,357
    Cost of Revenue 5,498 4,519 4,793 5,627

    Cost of revenue $20.4m inventory on hand end of year $14.8m (over 9 months of inventory sitting in a warehouse)
    Cost of inventory thrown away $1.4m
    A scrap rate of less than 1% is normal for a well run company
    A scrap rate of almost 7% is due to excess inventory.
    All signs of a company that does not fully understand what actual sales will be and guessed that sales should have been double of current levels.
    So Impella sales volume is lower than company guesses, maybe that’s why a Siemens or other big company never purchased Impella

    My last word on this issue

  • agoodlaughtoday by agoodlaughtoday Jun 8, 2009 5:35 PM Flag

    We recorded write-downs of inventory in the amount of $1.4 million, $1.0 million, and $0.2 million for fiscal 2009, 2008, and 2007, respectively.

  • Reply to

    THOR sales up

    by agoodlaughtoday May 7, 2009 8:56 PM
    agoodlaughtoday agoodlaughtoday May 12, 2009 8:25 PM Flag

    core product line keeps losing sales not a good sign. If not for Abiocor Hosp sale core product line down nearing 50%. That's why the large increase in inventory (dropped last qtr)and my guess why they had a layoff earlier in year

  • agoodlaughtoday by agoodlaughtoday May 7, 2009 8:56 PM Flag

    THOR is up Abio is reporting year end sales #'s a week later than normal. Core product sales have been dropping need I say more

AMRI
14.19-0.58(-3.93%)Aug 24 4:00 PMEDT